{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:14:17Z","timestamp":1774491257868,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06271"],"award-info":[{"award-number":["23K06271"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xphs.2026.104191","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:09:56Z","timestamp":1770311396000},"page":"104191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitigation of dose-dependent cilostazol absorption from cocrystals: A coformer regulates gastric dissolution and absorption profiles"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1124-9788","authenticated-orcid":false,"given":"Takato","family":"Masada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohdai","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saito","family":"Akei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-9361","authenticated-orcid":false,"given":"Keiko","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-4015","authenticated-orcid":false,"given":"Toshihide","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-9958","authenticated-orcid":false,"given":"Shinji","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-3174","authenticated-orcid":false,"given":"Makoto","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104191_bib0001","unstructured":"US Food and Drug Administration, Guidance for industry, Regulatory Classification of Pharmaceutical Co-Crystals. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulatory-classification-pharmaceutical-co-crystals, Accessed 5 January 2026."},{"issue":"28","key":"10.1016\/j.xphs.2026.104191_bib0002","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1021\/ja035776p","article-title":"Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids","volume":"125","author":"Remenar","year":"2003","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.xphs.2026.104191_bib0003","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1021\/cg0496540","article-title":"Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration remedy for caffeine hydration","volume":"5","author":"Trask","year":"2005","journal-title":"Cryst Growth Des"},{"issue":"11","key":"10.1016\/j.xphs.2026.104191_bib0004","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s11095-008-9676-2","article-title":"Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds","volume":"25","author":"Shiraki","year":"2008","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2026.104191_bib0005","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/j.2042-7158.2010.01189.x","article-title":"Bioavailability of indomethacin-saccharin cocrystals","volume":"62","author":"Jung","year":"2010","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104191_bib0006","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/acs.cgd.9b01688","article-title":"Drug\u2013drug cocrystals provide significant improvements of drug properties in treatment with progesterone","volume":"20","author":"Guo","year":"2020","journal-title":"Cryst Growth Des"},{"issue":"11","key":"10.1016\/j.xphs.2026.104191_bib0007","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1021\/acs.molpharmaceut.1c00537","article-title":"In vitro-in vivo correlation in cocrystal dissolution: consideration of drug release profiles based on coformer dissolution and absorption behavior","volume":"18","author":"Kataoka","year":"2021","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2026.104191_bib0008","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1021\/acs.molpharmaceut.2c00122","article-title":"Synchronization of cocrystal dissolution and drug precipitation to sustain drug supersaturation","volume":"19","author":"Cogo Machado","year":"2022","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104191_bib0009","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1021\/acs.cgd.6b01434","article-title":"Harvesting potential dissolution advantages of soluble cocrystals by depressing precipitation using the common coformer effect","volume":"16","author":"Yamashita","year":"2016","journal-title":"Cryst Growth Des"},{"issue":"8","key":"10.1016\/j.xphs.2026.104191_bib0010","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1021\/acs.molpharmaceut.3c00237","article-title":"Control of dissolution and supersaturation\/precipitation of poorly water-soluble drugs from cocrystals based on solubility products: a case study with a ketoconazole cocrystal","volume":"20","author":"Kataoka","year":"2023","journal-title":"Mol Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104191_bib0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2015.06.009","article-title":"Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol","volume":"491","author":"Sai Gouthami","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104191_bib0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.colsurfb.2017.03.017","article-title":"Comparison of three different types of cilostazol-loaded solid dispersion: Physicochemical characterization and pharmacokinetics in rats","volume":"154","author":"Mustapha","year":"2017","journal-title":"Colloids Surf B"},{"issue":"1-2","key":"10.1016\/j.xphs.2026.104191_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2005.11.013","article-title":"Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs","volume":"111","author":"Jinno","year":"2006","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2026.104191_bib0014","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1208\/s12249-009-9249-7","article-title":"Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes","volume":"10","author":"Patel","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2026.104191_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119759","article-title":"Osmotic pump tablets with solid dispersions synergized by hydrophilic polymers and mesoporous silica improve in vitro\/in vivo performance of cilostazol","volume":"588","author":"Zhang","year":"2020","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0016","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1248\/cpb.c24-00732","article-title":"Physical properties for novel cilostazol co-amorphous; effect of preparation method and molar ratio on the co-amorphous","volume":"73","author":"Takayama","year":"2025","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"2","key":"10.1016\/j.xphs.2026.104191_bib0017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/acs.cgd.6b01425","article-title":"Impact of the dissolution profile of the cilostazol cocrystal with supersaturation on the oral bioavailability","volume":"17","author":"Yoshimura","year":"2017","journal-title":"Cryst Growth Des"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0018","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1021\/acs.molpharmaceut.0c01207","article-title":"In Vitro sensitivity analysis of the gastrointestinal dissolution profile of weakly basic drugs in the stomach-to-intestine fluid changing system: explanation for variable plasma exposure after oral administration","volume":"18","author":"Takagi","year":"2021","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2026.104191_bib0019","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1002\/jps.24112","article-title":"Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution","volume":"103","author":"Takeuchi","year":"2014","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0020","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/acs.molpharmaceut.6b00824","article-title":"In vivo predictive dissolution (IPD) and biopharmaceutical modeling and simulation: future use of modern approaches and methodologies in a regulatory context","volume":"14","author":"Lennern\u00e4s","year":"2017","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1208\/s12248-018-0231-8","article-title":"The BioGIT system: a valuable in vitro tool to assess the impact of dose and formulation on early exposure to low solubility drugs after oral administration","volume":"20","author":"Kourentas","year":"2018","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104191_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2020.03.013","article-title":"Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations","volume":"151","author":"Schick","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104191_bib0023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/acs.molpharmaceut.3c01059","article-title":"Quabodepistat (OPC-167832), a novel antituberculosis drug candidate: enhancing oral bioavailability via cocrystallization and mechanistic analysis of bioavailability in two cocrystals","volume":"21","author":"Sakamoto","year":"2024","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/clpt.2011.267","article-title":"Imaging of gastrointestinal absorption and biodistribution of an orally administered probe using positron emission tomography in humans","volume":"91","author":"Shingaki","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2026.104191_bib0025","doi-asserted-by":"crossref","first-page":"521","DOI":"10.6028\/jres.035.026","article-title":"Ultraviolet spectra and dissociation constants of p-hydroxybenzoic acid methyl, ethyl, n-butyl, and benzyl p-hydroxybenzoate and potassium p-phenolsulfonate","volume":"35","author":"Sager","year":"1945","journal-title":"J Res Natl Bur Stand"},{"issue":"3","key":"10.1016\/j.xphs.2026.104191_bib0026","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01312264","article-title":"Numerical deconvolution by least squares: use of prescribed input functions","volume":"6","author":"Cutler","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104191_bib0027","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jps.2600760607","article-title":"Evaluation of in vivo drug release by numerical deconvolution using oral solution data as weighting function","volume":"76","author":"Chan","year":"1987","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0028","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1208\/s12248-012-9389-7","article-title":"Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs","volume":"14","author":"Gao","year":"2012","journal-title":"AAPS J"},{"issue":"12","key":"10.1016\/j.xphs.2026.104191_bib0029","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1080\/03639045.2018.1503295","article-title":"Determination of precipitation inhibitory potential of polymers from amorphous solid dispersions","volume":"44","author":"Chavan","year":"2018","journal-title":"Drug Dev Ind Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2026.104191_bib0030","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3390\/pharmaceutics13111772","article-title":"Effect of surfactants and polymers on the dissolution behavior of supersaturable tecovirimat-4-hydroxybenzoic acid cocrystals","volume":"13","author":"Feng","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.xphs.2026.104191_bib0031","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/1567201819666220427123101","article-title":"Critical strategies for drug precipitation inhibition: a review with the focus on poorly soluble drugs","volume":"20","author":"Parmar","year":"2023","journal-title":"Curr Drug Deliv"},{"issue":"8","key":"10.1016\/j.xphs.2026.104191_bib0032","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1021\/mp400176y","article-title":"Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability","volume":"10","author":"Childs","year":"2013","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104191_bib0033","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17425247.2021.1860940","article-title":"Sacubitril-valsartan cocrystal revisited: role of polymer excipients in the formulation","volume":"18","author":"Zhang","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104191_bib0034","unstructured":"National Institute of Health Sciences (NIHS). Toxicological information on 4-hydroxybenzoic acid (CAS 99-96-7). Drug Risk Assessment Database (DRA). Available at: https:\/\/dra4.nihs.go.jp\/mhlw_data\/home\/file\/file99-96-7.html, Accessed 5 January 2026."},{"issue":"1","key":"10.1016\/j.xphs.2026.104191_bib0035","article-title":"IUPAC-NIST Solubility Data Series. 90. Hydroxybenzoic acid derivatives in binary, ternary, and multicomponent systems. Part I. Hydroxybenzoic acids, hydroxybenzoates, and hydroxybenzoic acid salts in water and aqueous systems","volume":"40","author":"Goto","year":"2011","journal-title":"J Phys Chem Ref"},{"issue":"8","key":"10.1016\/j.xphs.2026.104191_bib0036","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1021\/acs.cgd.2c00370","article-title":"Two cocrystals of olaparib with flavonoids toward sustained release: structure, dissolution behavior, and anticancer activity analysis","volume":"22","author":"Duan","year":"2022","journal-title":"Cryst Growth Des"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:32:53Z","timestamp":1774488773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022354926000407"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104191","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigation of dose-dependent cilostazol absorption from cocrystals: A coformer regulates gastric dissolution and absorption profiles","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104191"}}